The Effects of Xuefu Zhuyu and Shengmai on the Evolution of Syndromes and Inflammatory Markers in Patients with Unstable Angina Pectoris after Percutaneous Coronary Intervention : A Randomised Controlled Clinical Trial

• Published in: Evidence-based complementary and alternative medicine Vol. 2013; no. 2013; pp. 1 - 9
• Main Authors: Wang, Jie, Yang, Xiaochen, Chu, Fuyong, Chen, Jianxin, He, Qingyong, Yao, Kuiwu, Teng, Fei, Gao, Yonghong, Xing, Yanhui, Ai-Ming, Wu, Yan-Wei, Xing
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Puplishing Corporation 01.01.2013; Hindawi Publishing Corporation; Hindawi Limited
• Subjects: Angina; Angina pectoris; Angioplasty; C-reactive protein; Cardiology; Cardiovascular disease; Chinese medicine; Clinical trials; Coronary vessels; Cytokines; Endothelin 1; Evidence-based medicine; Evolution; Gelatinase B; Heart attacks; Holism; Homocysteine; Inflammation; Integrative medicine; Ischemia; Stents; United States > US; China
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2013/896467

We evaluated the effects of the Xuefu Zhuyu capsule (XFZY) and the Shengmai capsule (SM) on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris (UAP) after percutaneous coronary intervention (PCI). Ninety patients with UAP after PCI were randomly and equally assigned to three groups: the XFZY group, the SM group, and the placebo group, with 30 patients in each group. Six syndrome factors (including Qi deficiency, yin deficiency, yang deficiency, blood stasis, phlegm, and Qi stagnation) and 4 inflammatory markers (high-sensitivity C-reactive protein (Hs-CRP), endothelins-1 (ET-1), matrix metalloproteinases-9 (MMP-9), and homocysteine (Hcy)) were observed at week 0 and at the 1st, 4th and 12th weeks. In conclusion, the evolution of syndromes present in patients with UAP after PCI followed these trends (1) The deficiency syndromes gradually increased during a 12-week period, but the excess syndromes first gradually decreased and then mildly increased after PCI. (2) XFZY and SM can prevent excess syndromes from increasing in the later stages and prevent deficiency syndromes from increasing in all stages. (3) XFZY and SMcan reduce the levels of the inflammatory markers, especially in the later stages after PCI.